Literature DB >> 1565477

Transforming growth factor beta 1 (TGF-beta 1) inhibits retinoblastoma gene expression but not pRB phosphorylation in TGF-beta 1-growth stimulated colon carcinoma cells.

Z Yan1, S Hsu, S Winawer, E Friedman.   

Abstract

The response of the retinoblastoma (RB) gene and its product (pRB) to transforming growth factor beta 1 (TGF-beta 1) was studied in three types of colon carcinoma cells derived from the same parental line. TGF-beta 1 was a growth inhibitor for two enterocytic-differentiated lines, a growth stimulator for two undifferentiated lines, and had no effect on two goblet cell-differentiated lines. TGF-beta 1 treatment for 3 days decreased RB gene expression and pRB level two- to threefold in each responsive line. When treated with TGF-beta 1 beginning in early G1, enterocytic cells were arrested in G1 and pRB remained under-phosphorylated and in low abundance. Neither goblet cell line exhibited these responses to TGF-beta 1 because they were shown to lack TGF-beta 1 type I and II receptors. Thus during colonocyte differentiation goblet cells lose responsiveness to TGF-beta 1 by down-regulating TGF-beta 1 receptors, while enterocytic cells retain and exhibit responsiveness to TGF-beta 1 through modulations of pRB. Both of the undifferentiated lines exhibited mixed responses to TGF-beta 1: a decrease in total amount of RB mRNA and pRB protein yet an increase in pRB phosphorylation consistent with increased cell cycling. Therefore, TGF-beta 1 controls RB function by two separable mechanisms, the regulation of pRB phosphorylation and the control of RB mRNA and protein level.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565477

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

Review 1.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

2.  Interactions between interferon gamma and retinoic acid with transforming growth factor beta in the induction of immune recognition molecules.

Authors:  R Darley; A Morris; J Passas; W Bateman
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

3.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

Authors:  B I Dalal; P A Keown; A H Greenberg
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient.

Authors:  M Olive; S Untawale; R J Coffey; M J Siciliano; D M Wildrick; H Fritsche; S Pathak; L M Cherry; M Blick; P Lointier
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 5.  Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm.

Authors:  R S Kerbel
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

6.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors:  C Lu; R S Kerbel
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

7.  Transforming growth factor beta: is it a downregulator of stem cell inhibition by macrophage inflammatory protein 1 alpha?

Authors:  J Maltman; I B Pragnell; G J Graham
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.